Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

8.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
8.0K
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

10.0K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
10.0K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.0K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.0K
Mitochondrial Precursor Proteins01:39

Mitochondrial Precursor Proteins

3.9K
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70  chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Cholecystectomy on Gastric Mucosal c-MYC and h-TERT Expression; A Potential Link to Gastric Cancer Development.

Balkan journal of medical genetics : BJMG·2026
Same author

Bilateral Alternate Orbital and Ocular Manifestations in a VEXAS Syndrome Patient.

Ocular immunology and inflammation·2025
Same author

Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis.

The British journal of dermatology·2021
Same author

Increased Expression of Pentraxin 3 in Placental Tissues from Patients with Unexplained Recurrent Pregnancy Loss.

Balkan journal of medical genetics : BJMG·2019
Same author

ROSACEA IS ASSOCIATED WITH THYROID AUTOIMMUNITY: A CASE CONTROL STUDY.

Acta endocrinologica (Bucharest, Romania : 2005)·2019
Same author

EFFECTIVENESS OF <i>ANETHUM GRAVEOLENS L.</i> ON ANTIOXIDANT STATUS, THYROID FUNCTION AND HISTOPATHOLOGY.

Acta endocrinologica (Bucharest, Romania : 2005)·2019

Related Experiment Video

Updated: Mar 17, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.5K

MEFV gene variation R202Q is associated with metabolic syndrome.

A Balkarli1, M Akyol, E Tepeli

  • 1Department of Internal Medicine, Division of Rheumatology, Antalya Training and Research Hospital, Muratpaşa, Antalya, Turkey. drayseayan@yahoo.com.tr.

European Review for Medical and Pharmacological Sciences
|July 29, 2016
PubMed
Summary

Genetic variations in the MEFV gene, particularly the R202Q mutation, are linked to metabolic syndrome. This finding suggests a potential role for MEFV gene variations in the development of metabolic syndrome.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.5K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Inflammation

Background:

  • The MEFV gene encodes pyrin, regulating inflammatory responses.
  • MEFV gene variations are linked to heightened acute phase responses and altered inflammatory disease courses.
  • These variations may influence the progression of metabolic syndrome components.

Purpose of the Study:

  • To investigate the association between MEFV gene variations and metabolic syndrome.
  • To determine if specific MEFV gene mutations are more prevalent in individuals with metabolic syndrome.

Main Methods:

  • Study included 50 metabolic syndrome patients and 50 healthy controls.
  • Genomic DNA was isolated, and exons 2 and 10 of the MEFV gene were analyzed using Sanger sequencing.
  • Statistical analysis was performed to compare gene variation frequencies and assess associations.

Main Results:

  • MEFV gene variations were found in 42% of metabolic syndrome patients and 24% of controls (p=0.55).
  • High penetrance variations (M694V, M680I, V726A) showed similar frequencies between groups (p>0.05).
  • The R202Q mutation was significantly more frequent in the metabolic syndrome group (22% vs. 6%, p=0.021, OR=4.42), indicating an association.

Conclusions:

  • This study is the first to report an association between metabolic syndrome and the MEFV R202Q mutation.
  • Familial Mediterranean fever-related MEFV gene variations may contribute to the pathogenesis of metabolic syndrome.